article · ESMO Open

83P A single-arm meta-analysis of the safety and efficacy of erdafitinib in patients with FGFR-altered urothelial carcinoma and solid tumors previously treated with systemic therapy

Mohamed Arafa
Yaqeen Alsheyab
Mahmoud Elsawy
Ahmad R. Al‐Qudimat
Muhamad Rifa’i
Ahmed Ibrahim Ahmed
Laila Shalabi
M. Asif
Sofian Zreigh
Ahmed Al Sakini
Amr Ehab El‐Qushayri

2025Open accessAlexandria University

Abstract

Erdafitinib is a pan-FGFR inhibitor approved for treating locally advanced or metastatic urothelial carcinoma and solid tumors with FGFR alterations after previous systemic therapy. We aim to evaluate its safety and efficacy in patients with FGFR-altered solid tumors, including urothelial carcinoma.

Research topics

Bladder and Urothelial Cancer Treatments
Fibroblast Growth Factor Research
Metastasis and carcinoma case studies

Sustainable Development Goals

3Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1016/j.esmoop.2025.104242

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.